Biocept Appoints Philippe Marchand as Chief Operating Officer
08 Março 2022 - 10:17AM
Business Wire
Industry veteran to oversee operations for the
company and its CNSide™ cerebrospinal fluid assay to aid in the
management of patients with metastatic brain cancers
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, has appointed Philippe
Marchand, Ph.D., to the position of Chief Operating Officer,
effective today. Dr. Marchand will be responsible for advancing the
company’s strategic and operational objectives, including all
laboratory operations of its CNSide cerebrospinal fluid assay,
which helps physicians better detect and manage treatment of
patients with metastatic cancers involving the central nervous
system.
“Biocept is excited to welcome an executive of Philippe’s
caliber to our team as we work to establish CNSide as the
standard-of-care diagnostic test for patients with metastatic
cancers involving the brain or spinal cord,” said Sam Riccitelli,
Biocept’s Chairman, and Interim President and CEO. “He shares our
strong belief that having a quantitative method to analyze tumor
cells in the cerebrospinal fluid will be key to improving care for
these patients.”
Dr. Marchand is a veteran biotechnology executive and scientist
with a proven track record in transitioning concepts to
implementation and commercialization. Most recently, Dr. Marchand
was the Chief Operating Officer of Biosplice Therapeutics, aiding
in the development of first-in-class small-molecule therapeutics.
Previously, he was the Chief Information Officer of Genoptix, where
he oversaw the creation of the company’s diagnostics laboratory,
and was instrumental in its IPO and subsequent acquisition by
Novartis. Following the acquisition, he assumed responsibilities
for global IT operations for Novartis Oncology.
“As the medical community develops new targeted therapies for
metastatic brain cancers, it is imperative to have more
sophisticated diagnostic tests available to characterize tumor
cells in the cerebrospinal fluid, identify treatment targets, and
monitor response to therapy,” Dr. Marchand said. “I am impressed
with the enormous progress Biocept has made in the development and
commercialization of CNSide, and look forward to helping take the
company and assay to the next level for the benefit of patients and
physicians.”
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes cerebrospinal fluid
tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to the ability of
CNSide to impact life expectancy and quality of life, our ability
to establish CNSide as the new standard of care for the diagnosis
of patients with suspected cancer metastasis to the CNS, our
ability to expand our CSF testing menu for additional tumor types
and biomarkers in the future, and our ability to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with a variety of cancers, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220308005446/en/
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024